ClinicalTrials.gg

Cerebral Infarction clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 219 studies for Cerebral Infarction across more than 10 countries. 46 are recruiting or about to start. 125 of them are mainly about Cerebral Infarction (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-21. Counting its 2 narrower conditions too, such as Infarction, Middle Cerebral Artery: 289 studies, 69 open.

Status

Completed
104
Status unknown
41
Recruiting
27
Terminated
18
Not yet recruiting
17
Withdrawn
5

Phase

Phase 2
35
Phase 4
29
Phase 3
28
Phase 1
10
Early Phase 1
1

Where

China
58
United States
23
France
22
Korea, Republic of
19
Canada
10
United Kingdom
9

Who develops what

Add Cerebral Infarction to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
GlycineRecent, limited
Evidence
  • NCT07575984 · Pharmasoft · Phase 4 · live · comparator · “Glycine” · registered May 2026
—11 study
AspirinEarlier onlyPhase 4 trial recorded
Evidence
  • NCT00234065 · Otsuka Holdings Co., Ltd. · Phase 4 · comparator · “Aspirin” · registered Oct 2005
  • NCT00129805 · Tanabe Pharma Corporation · Phase 3 · comparator · “Aspirin” · registered Aug 2005
Bayer25% of its industry studies00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Apr 2027 est.emoxypine succinate · Pharmasoft · Phase 4 registry mapping onlyvs GlycineNCT07575984 Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke — primary endpoint: Infarct Volume at Visit 2 (Day 11) · 120 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cerebral Infarction studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Factor Xa inhibitors 1 open · P2Y12 inhibitors 1 open · Thrombolytics 5

Coming up

8studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8, phase 3 first

Who these studies take

Of the 27 Cerebral Infarction studies recruiting now, 19 (70%) set no upper age limit and 0 (0%) stop at 75 or younger. 2 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (7%) take healthy volunteers.

Recruiting studies that take each age, of 27
AgeWomenMen
102 (7%)2 (7%)
1822 (81%)22 (81%)
3024 (89%)24 (89%)
4024 (89%)24 (89%)
5025 (93%)25 (93%)
6527 (100%)27 (100%)
7527 (100%)27 (100%)
8521 (78%)21 (78%)

Across all 219 studies, recruiting or not: 15% stop at 75 or younger and 7% at 65; 11% take children; 0% are for women only and 1% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cerebral Infarction studies take

Of 32 observational studies under Cerebral Infarction, half reached primary completion within 61 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase28 mo16–49 · 27 studies——
Observational61 mo14–167 · 32 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 219. Browse all 219 → or search them.